
|Articles|December 9, 2012
Elisabeth M. Paietta, PhD, Defines Minimum Residual Disease (MRD) and Discusses the Current Challenges of MRD Implementation
Elisabeth M. Paietta, PhD, Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, defines minimum residual disease (MRD) and discusses its clinical significance. She then describes the methodological and therapeutic challenges that face clinical MRD implementation.
Advertisement
Elisabeth M. Paietta, PhD, Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, defines minimum residual disease (MRD) and discusses its clinical significance. She then describes the methodological and therapeutic challenges that face clinical MRD implementation.
This video was taken on Sunday, December 9, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
2
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
3
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
4
Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes
5




